WILMINGTON, DEL. (November 14, 2025) – In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be effective for patients with metastatic colorectal cancer (CRC) refractory to ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...

Drug resistance has long turned some of the most advanced lung cancer therapies into temporary victories, with tumors learning to shrug off chemotherapy that once held them in check. A new wave of ...

Near the end of the classic 1942 movie Casablanca when Major Strasser is shot, Captain Renault famously pretends not to know who fired the gun and orders his officers to “round up the usual suspects.” ...

Gene-editing technologies show great promise for medical treatments and research, with the potential to cure thousands of ...

Scientists in China are about to become the first to use the game-changing gene-editing technology Crispr-Cas9 on humans. CRISPR allows scientists to easily add in or delete small bits of DNA in order ...

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...

Anticipated Key Milestones in 2026 CRISPR Therapeutics anticipates several key milestones across its portfolio: Continued global commercialization and adoption of CASGEVY, with ongoing quarterly ...